Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Regimens in Breast Cancer Subtypes
NCT02041338Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jan 2014
- Primary completion
- Dec 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and carboplatin in breast cancer (6 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Pathological Complete Response Rate. Status: unknown.
02
Drugs
paclitaxelcarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02041338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041338.